Monopar Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Monopar Therapeutics

08/05/2023 17:03

* Monopar Therapeutics Inc  MNPR.OQ   MNPR.O  is expected
to show
no change in quarterly revenue when it reports  results on May
10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Monopar
Therapeutics Inc
is for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Monopar
Therapeutics Inc is $6​, above​ its last closing price of $0.99.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.20       -0.20      -0.23     Missed  -12.2
 Sep. 30 2022  -0.21       -0.22      -0.19     Beat    12.6
 Jun. 30 2022  -0.20       -0.21      -0.22     Missed  -6.4​
 Mar. 31 2022  -0.22       -0.22      -0.19     Beat    14.6
 ​​Dec.                    -0.19      -0.21     Missed  -10.5
 31 2021                                                
 Sep. 30 2021  -0.19       -0.21      -0.20     Beat    5.9​
 Jun. 30 2021  -0.19       -0.19      -0.17     Beat    11.7
 Mar. 31 2021  -0.19       -0.19      -0.16     Beat    14.3
 This summary was machine generated May 8 at 16:03 GMT.  All
figures in US dollars  unless otherwise stated